Back to Search Start Over

Angiotensin-(1-7) Treatment Early in Life Prevents Cardiac Hypertrophy in Adult Hypertensive Rats.

Authors :
Pontes CNR
Bessa ASM
Macedo LM
Ferreira-Junior MD
Cavalcante KVN
Campos HM
Cruz-Leite VRM
Neves ÂR
Gomes RM
Ghedini PC
Biancardi MF
Mendes EP
Borges CL
Pedrino GR
Castro CH
Source :
Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2024 May 01; Vol. 83 (5), pp. 457-465. Date of Electronic Publication: 2024 May 01.
Publication Year :
2024

Abstract

Abstract: Angiotensin (Ang)-(1-7) is a cardioprotective peptide of the renin-angiotensin system. Prepuberty has been considered as a later susceptible window of development, and stressful factors in this life phase can induce chronic diseases in adulthood. We aimed to investigate whether the treatment with Ang-(1-7) during the prepuberty could attenuate the development of hypertension and cardiac injury in adult spontaneously hypertensive rats (SHRs). SHRs were treated with Ang-(1-7) (24 μg/kg/h) from age 4 to 7 weeks. Systolic blood pressure was measured by tail-cuff plethysmography up to 17th week. Thereafter, echocardiography was performed, and the rats were euthanized for the collection of tissues and blood. Ang-(1-7) did not change the systolic blood pressure but reduced the septal and posterior wall thickness, and cardiomyocyte hypertrophy and fibrosis in SHR. In addition, Ang-(1-7) reduced the gene expression of atrial natriuretic peptide and brain natriuretic peptide, increased the metalloproteinase 9 expression, and reduced the extracellular signal-regulated kinases 1/2 phosphorylation. Ang-(1-7) also prevented the reduction of Mas receptor but did not change the protein expression of angiotensin-converting enzyme, angiotensin-converting enzyme 2, AT1, and AT2. The treatment with Ang-(1-7) decreased the malondialdehyde (MDA) levels and increased superoxide dismutase-1 and catalase activities and protein expression of catalase. Our findings demonstrate that the treatment of SHR with Ang-(1-7) for 3 weeks early in life promotes beneficial effects in the heart later in life, even without altering blood pressure, through mechanisms involving the reduction of oxidative stress and ERK1/2 phosphorylation. In addition, this study supports the prepuberty as an important programming window.<br />Competing Interests: The authors declare no conflict of interest.<br /> (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1533-4023
Volume :
83
Issue :
5
Database :
MEDLINE
Journal :
Journal of cardiovascular pharmacology
Publication Type :
Academic Journal
Accession number :
38498600
Full Text :
https://doi.org/10.1097/FJC.0000000000001530